This report presents key results from the 2019 National Drug Strategy household survey. It looks at people’s drug use throughout their lives and during the last 12 months, and examines how these patterns have changed over time.
Smoking and vaping behaviours among 14 and 15-year-olds: results from the 2018 Youth Insights Survey
This report presents key findings from the 2018 Youth Insights Survey (YIS) about smoking and vaping behaviours among 14 and 15-year-olds. The study explores trends in these behaviours using the data from previous years’ surveys (2012-2018 YIS) as well as looks at access to cigarettes...
The evidence does not support the idea that e-cigarettes help people stop smoking.
Use of e-cigarettes and smoked tobacco in youth aged 14–15 years in New Zealand: findings from repeated cross-sectional studies (2014–19)
Media reports of a vaping epidemic among youth have raised concerns about the creation of a new generation of nicotine-dependent individuals who could graduate to cigarette smoking. This study investigated the use of e-cigarettes and cigarettes in the youth of New Zealand from 2014 to...
The borderless nature of the internet, coupled with narrow defnitions of advertising and interference, means the tobacco industry still uses online and social media to sell and promote its products, highlight supposed corporate social responsibility practices, and challenge public health views and policies.
In 2011 the New Zealand government set an ambitious goal to be smokefree by 2025. This means adult daily smoking is less than 5% prevalence and almost no new smokers start. To achieve this goal, this paper advocates a 'surge strategy.'
The HPA commissioned a qualitative research project to explore young Māori women’s attitudes towards vaping, their vaping behaviour, and the relationship between smoking and vaping. This report is a summary of the key findings.
This report is based on data about e-cigarettes in the 2017/18 New Zealand Smoking Monitor (NZSM) from 1,099 respondents.
This report maps the global, regional and national availability and use of safer nicotine products, the regulatory responses to these products, and the public health potential of tobacco harm reduction.